Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261210 | PMC |
| http://dx.doi.org/10.1007/s11739-020-02388-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Behçet's disease in pregnancy: a case report and literature review.
BMC Pregnancy Childbirth
January 2025
Department of Obstetrics and Gynecology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Longmatan Disrict, Chunhui Road 182, Luzhou, Sichuan, 646000, China.
Background: Behçet's disease (BD) during pregnancy is a relatively rare condition, and there are currently no established guidelines for its management. The effects of BD on both mothers and children remain unclear. In this paper, we present the diagnostic and treatment processes for a patient with BD during pregnancy.
View Article and Find Full Text PDFRetraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
Int J Antimicrob Agents
January 2025
IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address:
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.
BMC Cardiovasc Disord
December 2024
Community Memorial Hospital, Ventura, CA, USA.
Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study.
Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome.
Rivers at risks: The interplay of "COVID kit" medication misuse and urban waterway contaminants.
Chemosphere
February 2025
Laboratório de Fisiologia de Plantas sob Estresse, Departamento de Botânica, Setor de Ciências Biológicas, Universidade Federal do Paraná, Avenida Coronel Francisco H. dos Santos, 100, Centro Politécnico Jardim das Américas, C. P. 19031, Curitiba, 81531-980, Paraná, Brazil. Electronic address:
This study investigates the environmental impact of the widespread use of "COVID Kit" drugs-azithromycin (AZI), ivermectin (IVE), and hydroxychloroquine (HCQ)-in urban rivers of Curitiba in Brazil, during and after the COVID-19 pandemic. The research focuses on the occurrence and concentrations of these pharmaceuticals in water and sediment samples collected from key urban rivers. Concentrations of AZI, IVE, and HCQ in water ranged from 326 to 3340 ng/L, 130-3340 ng/L, and 304-3314 ng/L, respectively, while in sediment, they ranged from 18 to 249 ng/g, 21-480 ng/g, and 38-673 ng/g, respectively.
View Article and Find Full Text PDFRetraction notice to "Environmental impacts of COVID-19 treatment: Toxicological evaluation of azithromycin and hydroxychloroquine in adult zebrafish" [Sci. Total Environ. 790(2021) 148129].
Sci Total Environ
December 2024
Laboratrio de Pesquisas Biolgicas, Instituto Federal Goiano, Uruta, GO, Brazil; Programa de Ps-Graduao em Biotecnologia e Biodiversidade, Universidade Federal de Gois, Goinia, GO, Brazil; Programa de Ps-Graduao em Ecologia e Conservao de Recursos Naturais, Universidade Federal de Uberlndia, Uberlndia, MG, Brazil; Programa de Ps-Graduao em Conservao de Recursos Naturais do Cerrado, Instituto Federal Goiano, Uruta, GO, Brazil.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!